Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
The human Axin2 protein sequence is about 89% homologous to the mouse. The human Axin2 gene is located on the long arm of the chromosome (17q23-24), and its cDNA is about 2.5 kb long and consists of 10 exons. Axin2 encodes 843 amino acids (type a) or 778 amino acids (type b) of two isoforms, of which type b lacks the sixth exon and encodes 65 amino acids.
AXIN1 and AXIN2 certain domains of proteins showing a high similarity: The regulator AXIN tankyrases protein stability binding region mediates binding of RGS region APC, β-catenin- binding region and DIX region, etc. These two AXIN proteins are generally considered to be functionally identical, as Axin2 cDNA attenuates mouse damage caused by Axin1 deficiency. However, the functions of the two are not mutually replaceable. On day 9 of the embryonic stage, Axin1-deficient mice developed death, while Axin2 homozygous variant mice were reproducible with only minor skull abnormalities. The difference in the above phenotype may be due to the different expression of Axin1 and Axin2, Axin1 is ubiquitously expressed in different tissues and the expression of Axin2 is more temporally and spatially specific.
Guido and other studies have shown that the liver's microenvironment plays an important role in driving hepatic stem/progenitor cells (HpSC). The newly discovered third ecological site is around the hepatocytes, including Axin2 monoenergetic hepatocyte progenitor cells, whose lateral edges are connected to endothelial cells that are intended to be central veins, which contribute to the normal renewal of mature hepatocytes. Stem/progenitor cells are of great importance in the regenerative medicine of the liver and in the process leading to tissue diseases.
Axin2 and Wnt Pathways
Similar to Axin1, Axin2 protein also negatively regulates β-catenin-dependent Wnt signaling. Axin2 is a transcriptional target of β-catenin-dependent Wnt signaling, and Axin2 expression is elevated in tumors with abnormal activation of Wnt signaling pathway. Since the Wnt/β-catenin pathway promotes transcription of Axin2, AXIN2 can negatively regulate upstream molecules of the Wnt/β-catenin pathway. Therefore, elevated levels of Axin2 protein may be an important negative feedback mechanism for Wnt/β-catenin signaling in cells.
In normal cells, Axin2 acts as a negative regulator of the canonical Wnt signaling pathway. However, Axin2 is not a tumor suppressor gene but a potent cancer-promoting promoter that up-regulates the activity of the transcriptional inhibitor Snaill and induces EMT to stimulate metastatic activity. Studies have also found that the most important form of mutation in Axin2 is the carboxy-terminal deletion mutation (mutant Axin2, mtAxin2). mtAxin2 can cause elevated levels of β-catenin, suggesting that mtAxin2-bound β-catenin may not be phosphorylated and degraded. Wnt signaling system abnormalities are often accompanied by mitosis, apoptosis, and chromosomal instability. The Wnt signaling system is the key to cell development, and mtAxin2 plays a role in oncogenes.
Jo Waaler et al. showed that the small molecule inhibitor JW55, which uses the β-catenin signaling pathway, can inhibit the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2). This then leads to stabilization of Axin2, followed by an increase in the degradation of β-catenin.
A recent study by Chai et al. sought to determine how the Wnt/β-catenin signal is downregulated in the liver. By sequencing the small RNA isolated from the CD133+ and CD133-subpopulations of the PLC8024 HCC cell line, it was found that the expression of the microRNA miR-1246 was elevated in the CD133+ subpopulation. Since miR-1246 is predicted to target AXIN2 and GSK3β, the authors concluded that down-regulation of these genes by miR-1246 may drive HCC. After demonstrating that AXIN2 and GSK3β are directly targeted by miR-1246, they found that shRNA-mediated consumption of miR-1246 in HCC cells increased AXIN2 and GSK3β protein levels in the cytoplasm, decreased β-catenin levels in the nucleus and expression of the Wnt target gene.
Figure 1. Wnt/β-catenin activation and lower expression of Axin2 by miR-1246 in CD133+ liver CSCs, (Eshelman M A, et al. 2016)
Paul T. Sharpe et al. used TOPgal and BATgal reporter mice to study the expression of the classical Wnt signaling pathway antagonist Axin2 in tooth development. It can be seen that as the teeth develop, Axin2 precedes the primary enamel nodules and secondary enamel nodules and the mesenchyme below them. After the mouse was born, Axin2 was mainly expressed in the developing dentin, dental papilla and developing root regions, while Axin2 expression was not detected in the enamel cells and the non-enamel regions of the crown. These results indicate that the classical Wnt signaling pathway antagonist Axin2 plays an important role in enamel formation and root development in late tooth development.
Axin2 and Tumor
Researchers combined more than twenty proinflammatory mediators as a source, with thirty-one cancer genes as targets. Proinflammatory mediators are associated with cancer and the network is complex. This indicates that IL-1 and TADC act through the APC and p53 pathways, targeting the CDH1, p53 and AXIN2 genes. These genes are responsible for gastric cancer, colon cancer, breast cancer, brain cancer, and adrenal cancer. IL-8 and TAM act through the APC pathway that targets the AXIN2 gene, which is responsible for colon cancer. And studies have shown that Axin2 gene can play a role in malignant melanoma, gastric cancer and colon cancer.
Schaal et al. found that the aberrant activation of the Wnt / β-catenin pathway plays a major role in the development of colorectal cancer (CRC) and got conclusion that Axin2 is a key protein of this pathway and it is up-regulated in CRC. Aristizabalpachon et al. evaluated the AXIN2 rs2240308 and rs151279728 polymorphisms and the expression profile of β-catenin-destroying complex genes in breast cancer patients, demonstrating that AXIN2 gene defects and disruption of β-catenin disruption complex expression may be present in breast cancer patients.
Studies have shown that liver cancer stem cells (CSCs) initiate liver cancer. The research group also investigated the exact mechanism of the origin of CSCs in liver cirrhosis and liver cancer, and found that Met / JNK and Met / STAT3 signals in Axin2 + hepatocytes are activated by autophagy-dependent HGF expression, resulting in CD90 + CSCs of Axin2 + hepatocytes source, which is the main mechanism of liver cancer in liver cirrhosis. Hu et al. found that low Axin2 expression was associated with prostate cancer (PCa) recurrence after prostatectomy (RP), and its expression in PCa cells significantly affected invasiveness, proliferation, and tumor growth.
Reference:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.